PDCD1 and non-small cell lung carcinoma: Overall, the findings of this case indicate that cryotherapy for the acquired resistance to PD-1/PD-L1 and CTLA-4 axes immunotherapy for local control of NSCLC may provide a successful, safe and feasible strategy to complement immunotherapy in local control, bridging between systemic therapies and potentially overcoming the acquired resistance to checkpoint inhibition immunotherapies.